Skip to main content

Table 1 Clinical and radiologic characteristics of patients with intermediate to advanced hepatocellular carcinoma (HCC) who received transarterial chemoembolization (TACE) with or without H101

From: Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study

Variable

Overall [cases (%)]

TACE group [cases (%)]

TACE with H101 group [cases (%)]

P value

Age (years)

   

0.420

 ≤60

337 (70.8)

164 (68.9)

173 (72.7)

 

 >60

139 (29.2)

74 (31.1)

65 (27.3)

 

Sex

   

0.877

 Man

430 (90.3)

214 (89.9)

216 (90.8)

 

 Woman

46 (9.7)

24 (10.1)

22 (9.2)

 

WBC (×109/L)

   

0.693

 <10

449 (94.3)

223 (93.7)

226 (95.0)

 

 ≥10

27 (5.7)

15 (6.7)

12 (5.0)

 

PLT (×109/L)

   

0.123

 <100

58 (12.2)

35 (14.7)

23 (9.7)

 

 ≥100

418 (87.8)

203 (85.3)

215 (90.3)

 

ALT (U/L)

   

0.682

 <40

173 (36.3)

79 (33.2)

94 (39.5)

 

 ≥40

303 (63.7)

159 (66.8)

144 (60.5)

 

AST (U/L)

   

0.924

 <45

168 (35.3)

83 (34.9)

85 (35.7)

 

 ≥45

308 (64.7)

155 (65.1)

153 (64.3)

 

ALB (g/L)

   

0.417

 <35

63 (13.2)

35 (14.7)

28 (11.8)

 

 ≥35

413 (86.8)

203 (85.3)

210 (88.2)

 

TBIL (mmol/L)

   

0.066

 <20

381 (80.0)

182 (76.5)

199 (83.6)

 

 ≥20

95 (20.0)

56 (23.5)

39 (16.4)

 

IBIL (mmol/L)

   

0.011

 <15

431 (90.5)

207 (87.0)

224 (94.1)

 

 ≥15

45 (9.5)

31 (13)

14 (5.9)

 

ALP (U/L)

   

0.773

 <100

166 (34.9)

81 (34.0)

85 (35.7)

 

 ≥100

310 (65.1)

157 (66.0)

153 (64.2)

 

CRP (mg/L)

   

0.714

 <8.2

249 (52.3)

127 (53.4)

122 (51.2)

 

 ≥8.2

227 (47.7)

111 (46.6)

116 (48.8)

 

AFP (ng/mL)

   

0.923

 <25

164 (34.5)

81 (34.0)

83 (34.8)

 

 ≥25

312 (65.5)

157 (66.0)

155 (65.2)

 

HBsAg

   

0.046

 Negative

27 (5.7)

19 (8.0)

8 (3.4)

 

 Positive

449 (94.3)

219 (92.0)

230 (96.6)

 

HBV-DNA (IU/mL)

   

0.589

 <100

112 (23.5)

59 (24.8)

53 (22.2)

 

 ≥100

364 (76.5)

179 (75.2)

185 (77.8)

 

NLR

   

0.916

 <3

354 (74.4)

178 (74.8)

176 (73.9)

 

 ≥3

122 (25.6)

60 (25.2)

62 (26.1)

 

Tumor size (cm)

   

1.000

 <5

130 (27.3)

65 (27.3)

65 (27.3)

 

 ≥5

346 (72.7)

173 (72.7)

173 (72.7)

 

Tumor number

   

0.391

 Single

172 (36.1)

91 (38.2)

81 (34.0)

 

 Multiple

304 (63.9)

147 (61.8)

157 (66.0)

 

Splenomegaly

   

0.177

 No

311 (65.3)

148 (62.2)

163 (68.5)

 

 Yes

165 (34.7)

90 (37.8)

75 (31.5)

 

Metastasis

   

0.835

 No

452 (95.0)

227 (95.4)

225 (94.5)

 

 Yes

24 (5.0)

11 (4.6)

13 (5.5)

 

Vascular invasion

   

0.763

 No

336 (70.6)

170 (71.4)

166 (69.7)

 

 Yes

140 (29.4)

68 (28.6)

72 (30.3)

 

Antiviral therapy

   

0.066

 No

251 (52.7)

115 (48.3)

136 (57.1)

 

 Yes

225 (47.3)

123 (51.7)

102 (42.9)

 
  1. WBC white blood cell count, PLT platelet, ALT alanine transaminase, AST aspartate aminotransferase, ALB albumin, TBIL total bilirubin, IBIL indirect bilirubin, ALP alkaline phosphatase, CRP C-reactive protein, AFP alpha-fetoprotein, HBsAg surface antigen of hepatitis B virus, HBV hepatitis B virus, NLR neutrophil-to-lymphocyte ratio